LifeStance Health (US:LFST) Globenewswireยท2025-02-27 11:00Core Insights - LifeStance Health Group, Inc. reported strong financial performance for 2024, with a revenue growth of 19% year-over-year, reaching $1.251 billion, and a significant increase in Adjusted EBITDA by 103% to $119.7 million [3][5][6] Financial Highlights - Q4 2024 total revenue was $325.5 million, a 16% increase from Q4 2023 [4][5] - Full year 2024 revenue was $1,251.0 million, up from $1,055.7 million in 2023, marking a 19% increase [4][5] - Adjusted EBITDA for Q4 2024 was $32.8 million, a 62% increase from Q4 2023, and for the full year, it was $119.7 million [4][6][7] - The company reported a net loss of $7.1 million in Q4 2024, compared to a net loss of $45.0 million in Q4 2023, and a full year net loss of $57.4 million, down from $186.3 million in 2023 [4][5][6] Operational Metrics - The clinician base increased by 12% to 7,424 clinicians, with a net increase of 155 in Q4 2024 [5] - Visit volumes rose by 14% in Q4 2024 to 2.0 million, and for the full year, visit volumes increased by 15% to 7.9 million [5][6] Cash Flow and Balance Sheet - Net cash from operations for Q4 2024 was $62.3 million, totaling $107.3 million for the full year [5][8] - The company ended Q4 2024 with cash of $154.6 million and net long-term debt of $279.8 million [8] 2025 Guidance - LifeStance expects full year 2025 revenue to be between $1.40 billion and $1.44 billion, with a Center Margin of $440 million to $464 million, and Adjusted EBITDA of $130 million to $150 million [5][13]